Sameer Bansilal

Search results

• Anthos' blood thinner cuts the risk of bleeding amid race to develop safer anticoagulants

  Bansilal, S.

  13/11/23

  1 item of Media coverage

  Press/Media

• Bayer 2022: Getting past Roundup

  Bansilal, S.

  11/10/22

  1 item of Media coverage

  Press/Media

• Bayer’s KERENDIA® (finerenone) Receives Updated Label to Include Findings From Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes

  Bansilal, S.

  1/09/22 → 2/09/22

  3 items of Media coverage

  Press/Media

• Bayer’s KERENDIA® (finerenone) Receives Updated Label to Include Findings From Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes

  Bansilal, S.

  1/09/22

  1 item of Media coverage

  Press/Media

• Bayer’s KERENDIA® (finerenone) Receives Updated Label to Include Findings From Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes

  Bansilal, S.

  1/09/22

  9 items of Media coverage

  Press/Media

• Bayer’s KERENDIA® (finerenone) Receives New Recommendations From American Diabetes Association for Improving Cardiovascular Outcomes and Managing Patients With Chronic Kidney Disease Associated With Type 2 Diabetes

  Bansilal, S.

  28/06/22

  1 item of Media coverage

  Press/Media

• Bayer’s KERENDIA® (finerenone) Receives New Recommendations From American Diabetes Association for Improving Cardiovascular Outcomes and Managing Patients With Chronic Kidney Disease Associated With Type 2 Diabetes

  Bansilal, S.

  28/06/22

  1 item of Media coverage

  Press/Media

• Bayer's KERENDIA® (finerenone) Receives New Recommendations From American Diabetes Association for Improving Cardiovascular Outcomes and Managing Patients With Chronic Kidney Disease Associated With Type 2 Diabetes

  Bansilal, S.

  28/06/22

  5 items of Media coverage

  Press/Media

• Bayer Announces Recipients of the Second Annual Pulmonary Hypertension Accelerated Awards

  Bansilal, S.

  10/09/21

  1 item of Media coverage

  Press/Media

• Bayer Announces Recipients of the Second Annual Pulmonary Hypertension Accelerated Awards Coronary/Structural Heart September 10, 2021

  Bansilal, S.

  10/09/21

  2 items of Media coverage

  Press/Media

• Bayer Announces Recipients of the Second Annual Pulmonary Hypertension Accelerated Awards

  Bansilal, S.

  9/09/21 → 10/09/21

  12 items of Media coverage

  Press/Media

• Bayer Announces Publication of Phase IV Adempas® (riociguat) Data in The Lancet Respiratory Medicine Rhythm March 29, 2021

  Bansilal, S.

  29/03/21

  2 items of Media coverage

  Press/Media

• Bayer Announces Publication of Phase IV Adempas® (riociguat) Data in The Lancet Respiratory Medicine

  Bansilal, S.

  28/03/21 → 29/03/21

  15 items of Media coverage

  Press/Media

• Bayer Announces Publication of Phase IV Adempas® (riociguat) Data in The Lancet Respiratory Medicine

  Bansilal, S.

  29/03/21

  1 item of Media coverage

  Press/Media

• Bayer Phase IV Study Met its Primary Endpoint in PAH Patients Who Had Transitioned to Adempas® (riociguat) After Insufficient Response to PDE5 Inhibitors

  Bansilal, S.

  6/09/20 → 7/09/20

  13 items of Media coverage

  Press/Media

• #MedBikini vs JVS: Paper Spurs Debate Over Sexism, Social Media in Medicine

  Bansilal, S.

  30/07/20

  1 item of Media coverage

  Press/Media

• Bayer Launches the Second Annual Pulmonary Hypertension Accelerated Bayer (PHAB) Awards to Encourage and Recognize Innovation in Pulmonary Research

  Bansilal, S.

  1/06/20

  1 item of Media coverage

  Press/Media

• Bayer Launches the Second Annual Pulmonary Hypertension Accelerated Bayer (PHAB) Awards to Encourage and Recognize Innovation in Pulmonary Research; Awards program underscores the importance of critical clinical research to deepen understanding of pulmona

  Bansilal, S.

  1/06/20

  5 items of Media coverage

  Press/Media

• Bayer Announces Recipients of the Pulmonary Hypertension Accelerated Bayer (PHAB) Awards at CHEST Annual Meeting 2019

  Sulica, R., Trivieri, M. & Bansilal, S.

  21/10/19

  1 item of Media coverage

  Press/Media

• Bayer Announces Recipients of the Pulmonary Hypertension Accelerated Bayer (PHAB) Awards at CHEST Annual Meeting 2019

  Trivieri, M. & Bansilal, S.

  21/10/19

  1 item of Media coverage

  Press/Media

• Bayer Announces Recipients of the Pulmonary Hypertension Accelerated Bayer (PHAB) Awards at CHEST Annual Meeting 2019; -- Eight U.S. Researchers Working to Advance Pulmonary Hypertension (PH) Science and Care Awarded a Combined One Million Dollars in Gran

  Sulica, R., Trivieri, M. & Bansilal, S.

  21/10/19

  2 items of Media coverage

  Press/Media

• Bayer Announces Recipients of the Pulmonary Hypertension Accelerated Bayer (PHAB) Awards at CHEST Annual Meeting 2019; -- Eight U.S. Researchers Working to Advance Pulmonary Hypertension (PH) Science and Care Awarded a Combined One Million Dollars in Gran

  Sulica, R., Trivieri, M. & Bansilal, S.

  21/10/19

  1 item of Media coverage

  Press/Media

• Bayer Announces Recipients of the Pulmonary Hypertension Accelerated Bayer (PHAB) Awards at CHEST Annual Meeting 2019

  Sulica, R., Trivieri, M. & Bansilal, S.

  21/10/19

  1 item of Media coverage

  Press/Media

• Bayer Announces Recipients of the Pulmonary Hypertension Accelerated Bayer (PHAB) Awards at CHEST Annual Meeting 2019

  Sulica, R., Trivieri, M. & Bansilal, S.

  21/10/19

  4 items of Media coverage

  Press/Media

• Bayer Announces Recipients of the Pulmonary Hypertension Accelerated Bayer (PHAB) Awards at CHEST Annual Meeting 2019

  Sulica, R., Trivieri, M. & Bansilal, S.

  21/10/19

  1 item of Media coverage

  Press/Media